2. Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am Fam Physician 2007;75:56–63.
3. Jacobsen MM, Silverstein SC, Quinn M, Waterston LB, Thomas CA, Benneyan JC,
et al. Timeliness of access to lung cancer diagnosis and treatment: a scoping literature review. Lung Cancer 2017;112:156–164.
4. Hoy H, Lynch T, Beck M. Surgical treatment of lung cancer. Crit Care Nurs Clin North Am 2019;31:303–313.
5. Qian X, Zhao J, Yeung PY, Zhang QC, Kwok CK. Revealing lncRNA structures and interactions by sequencing-based approaches. Trends Biochem Sci 2019;44:33–52.
6. Nigita G, Marceca GP, Tomasello L, Distefano R, Calore F, Veneziano D,
et al. ncRNA editing: functional characterization and computational resources. Methods Mol Biol 2019;1912:133–174.
8. Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing miRNA-lncRNA interactions. Methods Mol Biol 2016;1402:271–286.
10. Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: biology, functions, therapeutics, and analysis methods. J Cell Physiol 2019;234:5451–5465.
11. Bak RO, Mikkelsen JG. miRNA sponges: soaking up miRNAs for regulation of gene expression. Wiley Interdiscip Rev RNA 2014;5:317–333.
13. Acunzo M, Romano G, Wernicke D, Croce CM. MiRNA and cancer: a brief overview. Adv Biol Regul 2015;57:1–9.
14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–674.
15. Sandiford OA, Moore CA, Du J, Boulad M, Gergues M, Eltouky H,
et al. Human aging and cancer: role of miRNA in tumor microenvironment. Adv Exp Med Biol 2018;1056:137–152.
16. Iacona JR, Lutz CS. miR-146a-5p: Expression, regulation, and functions in cancer. Wiley Interdiscip Rev RNA 2019;10:e1533.
18. Shen YY, Cui JY, Yuan J, Wang X. MiR-451a suppressed cell migration and invasion in non-small cell lung cancer through targeting ATF2. Eur Rev Med Pharmacol Sci 2018;22:5554–5561.
19. Jiang YJ, Bikle DD. LncRNA profiling reveals new mechanism for VDR protection against skin cancer formation. J Steroid Biochem Mol Biol 2014;144 Pt A:87–90.
22. Ma Y, Zhang J, Wen L, Lin A. Membrane-lipid associated lncRNA: a new regulator in cancer signaling. Cancer Lett 2018;419:27–29.
23. Wang X, Yin H, Zhang L, Zheng D, Yang Y, Zhang J,
et al. The construction and analysis of the aberrant lncRNA-miRNA-mRNA network in non-small cell lung cancer. J Thorac Dis 2019;11:1772–1778.
27. Qi X, Zhang DH, Wu N, Xiao JH, Wang X, Ma W. ceRNA in cancer: possible functions and clinical implications. J Med Genet 2015;52:710–718.
29. Li DS, Ainiwaer JL, Sheyhiding I, Zhang Z, Zhang LW. Identification of key long non-coding RNAs as competing endogenous RNAs for miRNA-mRNA in lung adenocarcinoma. Eur Rev Med Pharmacol Sci 2016;20:2285–2295.
31. Ren J, Fu J, Ma T, Yan B, Gao R, An Z,
et al. LncRNA H19-elevated LIN28B promotes lung cancer progression through sequestering miR-196b. Cell Cycle 2018;17:1372–1380.
33. Li S, Mei Z, Hu HB, Zhang X. The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis. J Cell Physiol 2018;233:6679–6688.
35. Zhen Q, Gao LN, Wang RF, Chu WW, Zhang YX, Zhao XJ,
et al. LncRNA DANCR promotes lung cancer by sequestering miR-216a. Cancer Control 2018;25:1073274818769849.
39. Tang Y, Wu L, Zhao M, Zhao G, Mao S, Wang L,
et al. LncRNA SNHG4 promotes the proliferation, migration, invasiveness, and epithelial-mesenchymal transition of lung cancer cells by regulating miR-98-5p. Biochem Cell Biol 2019;97:767–776.
41. Nie W, Ge HJ, Yang XQ, Sun X, Huang H, Tao X,
et al. LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p. Cancer Lett 2016;371:99–106.
42. Li Z, Lu Q, Zhu D, Han Y, Zhou X, Ren T. Lnc-SNHG1 may promote the progression of non-small cell lung cancer by acting as a sponge of miR-497. Biochem Biophys Res Commun 2018;506:632–640.
43. Yu W, Sun Z, Yang L, Han Y, Yue L, Deng L,
et al. lncRNA PTAR promotes NSCLC cell proliferation, migration and invasion by sponging microRNA101. Mol Med Rep 2019;20:4168–4174.
44. Imai D, Yoshizumi T, Okano S, Uchiyama H, Ikegami T, Harimoto N,
et al. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Cancer Med 2017;6:1614–1626.
45. Ahn BC, Pyo KH, Xin CF, Jung D, Shim HS, Lee CY,
et al. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. J Cancer Res Clin Oncol 2019;145:1613–1623.
46. Liu C, Yang Z, Deng Z, Zhou Y, Gong Q, Zhao R,
et al. Upregulated lncRNA ADAMTS9-AS2 suppresses progression of lung cancer through inhibition of miR-223-3p and promotion of TGFBR3. IUBMB Life 2018;70:536–546.
49. Hao XZ, Yang K. LncRNA MAGI2-AS3 suppresses the proliferation and invasion of non-small cell lung carcinoma through miRNA-23a-3p/PTEN axis. Eur Rev Med Pharmacol Sci 2019;23:7399–7407.
51. Liu X, Ma J, Xu F, Li L. TINCR suppresses proliferation and invasion through regulating miR-544a/FBXW7 axis in lung cancer. Biomed Pharmacother 2018;99:9–17.
52. Li Y, Zhao L, Zhao P, Liu Z. Long non-coding RNA LINC00641 suppresses non-small-cell lung cancer by sponging miR-424-5p to upregulate PLSCR4. Cancer Biomark 2019;26:79–91.
53. Zhang G, Wang Q, Zhang X, Ding Z, Liu R. LncRNA FENDRR suppresses the progression of NSCLC via regulating miR-761/TIMP2 axis. Biomed Pharmacother 2019;118:109309.
54. Zhuan B, Lu Y, Chen Q, Zhao X, Li P, Yuan Q,
et al. Overexpression of the long noncoding RNA TRHDE-AS1 inhibits the progression of lung cancer via the miRNA-103/KLF4 axis. J Cell Biochem 2019;120:17616–17624.
55. Ao X, Jiang M, Zhou J, Liang H, Xia H, Chen G. lincRNAp21 inhibits the progression of nonsmall cell lung cancer via targeting miR175p. Oncol Rep 2019;41:789–800.
57. Mei Y, Si J, Wang Y, Huang Z, Zhu H, Feng S,
et al. Long Noncoding RNA GAS5 suppresses tumorigenesis by inhibiting miR-23a rxpression in non-small cell lung cancer. Oncol Res 2017;25:1027–1037.
61. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW,
et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–2139.
63. Yang QS, Li B, Xu G, Yang SQ, Wang P, Tang HH,
et al. Long noncoding RNA LINC00483/microRNA-144 regulates radiosensitivity and epithelial-mesenchymal transition in lung adenocarcinoma by interacting with HOXA10. J Cell Physiol 2019;234:11805–11821.
64. Liu AM, Zhu Y, Huang ZW, Lei L, Fu SZ, Chen Y. Long noncoding RNA FAM201A involves in radioresistance of non-small-cell lung cancer by enhancing EGFR expression via miR-370. Eur Rev Med Pharmacol Sci 2019;23:5802–5814.
66. Chen ZY, Liu HY, Jiang N, Yuan JM. LncRNA HOST2 enhances gefitinib-resistance in non-small cell lung cancer by down-regulating miRNA-621. Eur Rev Med Pharmacol Sci 2019;23:9939–9946.
68. Wang L, Shang X, Feng Q. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis. Cancer Biol Ther 2019;20:261–271.
69. Zeng F, Wang Q, Wang S, Liang S, Huang W, Guo Y,
et al. Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression. Oncogene 2020;39:293–307.